Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium–glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors
Authors' conclusion
Our data indicated that SGLT2i, compared with DPP4i, were associated with lower risks of HFH, coronary revascularization, composite renal outcomes, and all-cause mortality for patients with T2D after PCI.
Study context
- Population
- Patients with T2DM who underwent percutaneous coronary intervention (PCI), nationwide, 1 May 2016–31 December 2019propensity-score matched
- Participants
- 4,248 vs 37,037
- Exposure
- SGLT2i vs DPP4i after PCI
- SGLT2in = 4,248
- DPP4in = 37,037reference
- Outcome
- CV, renal and lower limb outcomes
Methodological detailsnationwide, propensity-score matched, consecutive patients
- Nationwide
- Propensity-score matched
- Consecutive patients
Main finding
As reported in the abstract
SGLT2i
- HF hospitalization
- 1.35% per year
- Coronary revascularization
- 2.33% per year
- Composite renal outcomes
- 0.10% per year
- All-cause mortality
- 2.27% per year
DPP4i
- HF hospitalization
- 2.28% per year
- Coronary revascularization
- 3.36% per year
- Composite renal outcomes
- 1.05% per year
- All-cause mortality
- 3.80% per year
HF hospitalization
SGLT2i1.35% per year
DPP4i2.28% per year
Coronary revascularization
SGLT2i2.33% per year
DPP4i3.36% per year
Composite renal outcomes
SGLT2i0.10% per year
DPP4i1.05% per year
All-cause mortality
SGLT2i2.27% per year
DPP4i3.80% per year
- HF hospitalization
- HR 0.60; P = 0.0001
- Coronary revascularization
- HR 0.69; P = 0.0003
- Composite renal outcomes
- HR 0.17; P < 0.0001
- All-cause mortality
- HR 0.60; P < 0.0001
Observational data: associations, not effects.
Original publication
Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium–glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors. Eur Heart J Cardiovasc Pharmacother. Published 13 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →